2026 ICD-10-CM Diagnosis Code D3A.091Benign carcinoid tumor of the thymus

ICD-10-CM Codes›C00–D49›D3A›D3A

ICD-10-CM D3A.091
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D3A.091 is a billable ICD-10-CM diagnosis code for benign carcinoid tumor of the thymus. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 814 through 816. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Benign neoplasms.

For Medicare Advantage risk adjustment, D3A.091 maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers) under the V28 model, adding a risk factor of about 0.363 for a community, non-dual, aged beneficiary in payment year 2026.

Code Identity

ICD-10-CM Code
D3A.091
Billable Status
Yes — Valid for Submission
Code Describes
Benign carcinoid tumor of the thymus
Short Description
Benign carcinoid tumor of the thymus
Same as the full description in the CMS dataset.
Parent Code
D3A.09
Benign carcinoid tumors of other sites

Code Classification

ChapterC00–D49Neoplasms
SectionD3ABenign neuroendocrine tumors
CategoryD3ABenign neuroendocrine tumors
This CodeD3A.091Benign carcinoid tumor of the thymus

Medicare Risk Adjustment (HCC)Billing

D3A.091 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.

CMS-HCC V28 Category (Payment Model)
HCC 22— Bladder, Colorectal, and Other Cancers
Payment HCC · PY 2026 one of 126 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.363
community, non-dual, aged · ranges 0.314–0.410 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
Not mapped under V24
this diagnosis newly risk-adjusts under the V28 model
Part D (RxHCC)
RxHCC 22 — Prostate, Breast, Bladder, and Other Cancers and Tumors
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO073
Benign neoplasms
Default principal diagnosis: inpatient Yes · outpatient Yes

Patient EducationClinical

Benign Tumors

Tumors are abnormal growths in your body. They can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Benign tumors grow only in one place. They cannot spread or invade other parts of your body. Even so, they can be dangerous if they press on vital organs, such as your brain.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D3A.091 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
209.62 Benign carcinoid thymus
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D3A.091Overview

What is the ICD-10 code for benign carcinoid tumor of the thymus?

The ICD-10-CM code for benign carcinoid tumor of the thymus is D3A.091 (sometimes written as D3A091). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is D3A.091 (Benign carcinoid tumors of other sites) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report benign carcinoid tumor of the thymus on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D3A.091 group to?

When benign carcinoid tumor of the thymus is the principal diagnosis on an inpatient stay, it groups to MS-DRG 814, 815, 816, with relative weights from 0.6320 to 2.1267 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of D3A.091?

Under the General Equivalence Mappings, benign carcinoid tumor of the thymus converts to ICD-9-CM 209.62 (benign carcinoid thymus). The mapping is a direct match.

What HCC is D3A.091?

D3A.091 (benign carcinoid tumor of the thymus) maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers), commonly written as HCC 22, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. In the Part D prescription drug model it maps to RxHCC 22.

Does D3A.091 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, D3A.091 adds a risk adjustment factor of about 0.363 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.314 to 0.410 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21) supersedes it when both are reported. See the full factor table on the HCC 22 category page.